Acute myeloid leukemia with CPSF6-RARG fusion resembling acute promyelocytic leukemia with extramedullary infiltration.

Acute myeloid leukemia with CPSF6-RARG fusion resembling acute promyelocytic leukemia with extramedullary infiltration.
复制标题

CPSF6-RARG 融合的急性髓系白血病类似于伴有髓外浸润的急性早幼粒细胞白血病。

DOI:
10.1177/2040620720976984
复制
发表时间:
2021
影响因子:
3.4
通讯作者:
Cai Z
Cai Z
中科院分区:
医学2区
文献类型:
--
作者:
Han X;Jin C;Zheng G;Li Y;Wang Y;Zhang E;Zhu H;Cai Z

文献摘要

参考文献

被引文献

相似文献

急性髓系白血病(AML)的某些亚型具有急性早幼粒细胞白血病(APL)的形态、免疫表型和临床特征,但缺乏PML-RARA(早幼粒细胞白血病-维甲酸受体α)融合基因。相反,他们对维甲酸受体β(RARB)或维甲酸受体伽马(RARG)进行了重新排列。几乎所有这些AML亚型都表现出对全反式维甲酸(ATRA)的耐药性;毫无疑问,预后很差。在这里,我们介绍了一例类似APL的AML患者,具有一种新的切割和多聚腺苷化特异因子6(CPSF6)-RARG融合,显示出对ATRA的耐药性和对高三尖杉酯碱和阿糖胞苷化疗的不良反应。同时,患者也有髓外浸润。
Some subtypes of acute myeloid leukemia (AML) share morphologic, immunophenotypic, and clinical features of acute promyelocytic leukemia (APL), but lack a PML–RARA (promyelocytic leukemia–retinoic acid receptor alpha) fusion gene. Instead, they have the retinoic acid receptor beta (RARB) or retinoic acid receptor gamma (RARG) rearranged. Almost all of these AML subtypes exhibit resistance to all-trans retinoic acid (ATRA); undoubtedly, the prognosis is poor. Here, we present an AML patient resembling APL with a novel cleavage and polyadenylation specific factor 6 (CPSF6)–RARG fusion, showing resistance to ATRA and poor response to chemotherapy with homoharringtonine and cytarabine. Simultaneously, the patient also had extramedullary infiltration.
DOI: 10.1016/j.ccr.2010.11.015
发表时间: 2010-12-14
期刊: Cancer cell
影响因子: 50.3
作者:
Figueroa ME;Abdel-Wahab O;Lu C;Ward PS;Patel J;Shih A;Li Y;Bhagwat N;Vasanthakumar A;Fernandez HF;Tallman MS;Sun Z;Wolniak K;Peeters JK;Liu W;Choe SE;Fantin VR;Paietta E;Löwenberg B;Licht JD;Godley LA;Delwel R;Valk PJ;Thompson CB;Levine RL;Melnick A
通讯作者: Melnick A
DOI: 10.1016/j.ejrad.2015.11.019
发表时间: 2016-01-01
影响因子: 3.3
作者:
Zhou, Wen-lan;Wu, Hu-bing;Wang, Quan-shi
通讯作者: Wang, Quan-shi
DOI: 10.1158/2159-8290.cd-16-0160
发表时间: 2016-07
期刊: Cancer discovery
影响因子: 28.2
作者:
Kim E;Ilic N;Shrestha Y;Zou L;Kamburov A;Zhu C;Yang X;Lubonja R;Tran N;Nguyen C;Lawrence MS;Piccioni F;Bagul M;Doench JG;Chouinard CR;Wu X;Hogstrom L;Natoli T;Tamayo P;Horn H;Corsello SM;Lage K;Root DE;Subramanian A;Golub TR;Getz G;Boehm JS;Hahn WC
通讯作者: Hahn WC
EZH2 突变与骨髓中的低原始细胞百分比和新发急性髓系白血病中的 -7/del(7q) 有关。
DOI: 10.1371/journal.pone.0061341
发表时间: 2013
期刊: PloS one
影响因子: 3.7
作者:
Wang X;Dai H;Wang Q;Wang Q;Xu Y;Wang Y;Sun A;Ruan J;Chen S;Wu D
通讯作者: Wu D
DOI: 10.1182/bloodadvances.2017014183
发表时间: 2018-06-12
期刊: BLOOD ADVANCES
影响因子: 7.5
作者:
Miller, Christopher A.;Tricarico, Christopher;Wartman, Lukas D.
通讯作者: Wartman, Lukas D.